Tango Therapeutics (TNGX) Net Income towards Common Stockholders: 2020-2025
Historic Net Income towards Common Stockholders for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $15.9 million.
- Tango Therapeutics' Net Income towards Common Stockholders rose 154.46% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.5 million, marking a year-over-year increase of 18.57%. This contributed to the annual value of -$130.3 million for FY2024, which is 28.07% down from last year.
- Tango Therapeutics' Net Income towards Common Stockholders amounted to $15.9 million in Q3 2025, which was up 140.88% from -$38.9 million recorded in Q2 2025.
- Over the past 5 years, Tango Therapeutics' Net Income towards Common Stockholders peaked at $15.9 million during Q3 2025, and registered a low of -$39.9 million during Q1 2025.
- In the last 3 years, Tango Therapeutics' Net Income towards Common Stockholders had a median value of -$29.2 million in 2024 and averaged -$26.8 million.
- Per our database at Business Quant, Tango Therapeutics' Net Income towards Common Stockholders plummeted by 50,695.34% in 2021 and then spiked by 154.46% in 2025.
- Over the past 5 years, Tango Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$22.1 million in 2021, then slumped by 31.98% to -$29.1 million in 2022, then decreased by 5.65% to -$30.8 million in 2023, then fell by 22.37% to -$37.6 million in 2024, then spiked by 154.46% to $15.9 million in 2025.
- Its Net Income towards Common Stockholders stands at $15.9 million for Q3 2025, versus -$38.9 million for Q2 2025 and -$39.9 million for Q1 2025.